Status and phase
Conditions
Treatments
Study type
Funder types
Identifiers
About
This phase I trial studies how well itacitinib works for the treatment of bronchiolitis obliterans syndrome after donor hematopoietic cell transplant. Itacitinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
Full description
PRIMARY OBJECTIVE:
I. To assess the safety of itacitinib in patients with bronchiolitis obliterans syndrome (BOS) after allogeneic hematopoietic cell transplantation (HCT).
SECONDARY OBJECTIVES:
I. To assess treatment failure at 3 months and 6 months.
II. To assess change in symptom-based lung score at 3 months and 6 months.
III. To assess change in the St. George Respiratory Questionnaire and Study Short Form 36 at 3 months and 6 months.
IV. To assess change in the Lee chronic graft versus host disease (GVHD) symptom scale at 3 months and 6 months post-treatment.
V. To assess change in 6-minute walk test at 3 months and 6 months.
VI. To assess failure-free survival at 6 months.
VII. To assess non-relapse mortality at 6 months.
VIII. To assess overall survival at 6 months.
OUTLINE:
Patents receive itacitinib orally (PO) once daily (QD) for up to 1 year in the absence of disease progression or unacceptable toxicity.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Exclusion criteria
Primary purpose
Allocation
Interventional model
Masking
8 participants in 1 patient group
Loading...
Central trial contact
Amin Alousi, MD
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal